Adis, Auckland, New Zealand.
CNS Drugs. 2012 Sep 1;26(9):787-90. doi: 10.2165/11209440-000000000-00000.
Transdermal granisetron (Sancuso®) is effective in the prevention of nausea and vomiting in patients with cancer who are receiving moderately or highly emetogenic chemotherapy for 3-5 days. Transdermal granisetron is noninferior to oral granisetron in this indication, and is generally well tolerated in this indication. Thus, transdermal granisetron provides a convenient option for the prevention of chemotherapy-induced nausea and vomiting, with the potential to improve patient compliance.
透皮型格拉司琼(Sancuso®)对接受中高度致吐性化疗(3-5 天)的癌症患者预防恶心和呕吐有效。在该适应证中,透皮型格拉司琼不劣于口服格拉司琼,且在该适应证中总体耐受良好。因此,透皮型格拉司琼为预防化疗引起的恶心和呕吐提供了一种方便的选择,有可能提高患者的依从性。